Canary Advisors has partnered with Engage Health and Sarepta Therapeutics to gather meaningful input from families of patients treated with Sarepta’s exon-skipping phosphorodiamidate morpholino oligomer (PMO) therapies (Exondys, Vyondys, and Amondys). This effort is designed to better understand patient and caregiver treatment experiences beyond clinical data. The insights collected may help Sarepta gain a more comprehensive understanding of the real-world impact of exon-skipping PMO therapies. Participation involves a 30-minute conversation, with no preparation required. To begin, follow the link here to participate.